Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Homer

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|July 12, 2019
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsDeborah Ayeni, Braden Miller, Alexandra Kuhlmann, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 23, 2022
Development of an immunohistochemical assay for Siglec-15Saba Shafi, Thazin Nwe Aung, Charles Robbins, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2019
Differences in Pathology, Staging, and Treatment between HIV<sup>+</sup> and Uninfected Patients with Microscopically Confirmed Hepatocellular CarcinomaJessie Torgersen, Tamar H Taddei, Lesley S Park, et al.
Science Advances|August 25, 2020
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosisTaylor S Adams, Jonas C Schupp, Sergio Poli, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
Cancer Research|February 15, 2024
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular ContextsBomiao Hu, Marc Wiesehöfer, Fernando J de Miguel, et al.
American Journal of Respiratory and Critical Care Medicine|October 14, 2016
SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary FibrosisArgyrios Tzouvelekis, Guoying Yu, Christian L Lino Cardenas, et al.
Nature Communications|June 6, 2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosisWilliam Damsky, Alice Wang, Daniel J Kim, et al.
JAMA Oncology|March 10, 2017
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung CancerDavid L Rimm, Gang Han, Janis M Taube, et al.
Cancer Research|October 17, 2008
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer riskLena J Chin, Elena Ratner, Shuguang Leng, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|July 12, 2019
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumorsDeborah Ayeni, Braden Miller, Alexandra Kuhlmann, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|April 23, 2022
Development of an immunohistochemical assay for Siglec-15Saba Shafi, Thazin Nwe Aung, Charles Robbins, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 3, 2019
Differences in Pathology, Staging, and Treatment between HIV<sup>+</sup> and Uninfected Patients with Microscopically Confirmed Hepatocellular CarcinomaJessie Torgersen, Tamar H Taddei, Lesley S Park, et al.
Science Advances|August 25, 2020
Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosisTaylor S Adams, Jonas C Schupp, Sergio Poli, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
Cancer Research|February 15, 2024
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular ContextsBomiao Hu, Marc Wiesehöfer, Fernando J de Miguel, et al.
American Journal of Respiratory and Critical Care Medicine|October 14, 2016
SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary FibrosisArgyrios Tzouvelekis, Guoying Yu, Christian L Lino Cardenas, et al.
Nature Communications|June 6, 2022
Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosisWilliam Damsky, Alice Wang, Daniel J Kim, et al.
JAMA Oncology|March 10, 2017
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung CancerDavid L Rimm, Gang Han, Janis M Taube, et al.
Cancer Research|October 17, 2008
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer riskLena J Chin, Elena Ratner, Shuguang Leng, et al.
Pageof 7